Science

Apr 11, 2025, 10:40

Myeloma Paper of the Day, April 11th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with ide-cel finds link of major microbiome disruption with increased CRS risk/severity; may help develop ways to improve CAR-T outcomes.”

“Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel”

Authors: Satabdi Saha, Lubna Rehman, Abdur Rehman, Faezeh Darbaniyan, Donna Weber, Michael Jain, Christine Peterson, Doris Hansen, Neeraj Saini, Krina Patel et al.

More posts featuring Robert Orlowski.

Abdur Rehman cancer Christine Peterson Donna Weber Doris Hansen Faezeh Darbaniyan Krina Patel Lubna Rehman Michael Jain multiple myeloma Myeloma Paper of the Day Neeraj Saini OncoDaily Oncology Robert Orlowski Satabdi Saha

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research

Stella Kyriakides joins ESO as Co-Chair and Senior Lecturer in Cancer Policy to Guide the 2026–2028 Strategic Plan

FDA Approves Nivolumab and Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer: CheckMate 8HW trial results